Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Multiple Sclerosis: The History of a Disease won a 2005 ForeWord Book of the Year Silver Medal! The basic facts about multiple sclerosis are well known: it is the most common neurologic disease of young adults, usually beginning with episodic attacks of neurologic symptoms, then entering a progressive phase some years later. Its onset has an average age of 30, and occurs in about 1 in 500 individuals of European ancestry living primarily in temperate climates. There appears to be a complex interaction between a genetic predisposition...

Multiple sclerosis --- MS (Disease) --- Sclerosis, Multiple --- Demyelination --- Myelin sheath --- Virus diseases --- History. --- Diseases --- Multiple Sclerosis --- history.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The recent explosion of new information about the pathology, pathophysiology, clinical classification, imaging, and treatment of multiple sclerosis (MS) has dramatically opened the way to a deeper understanding of the disease and a more effective therapeutic landscape for patients. In Multiple Sclerosis: Etiology, Diagnosis, and New Treatment Strategies, leading MS physicians synthesize current concepts about the evaluation, treatment, and future directions in MS. On the evaluation side, the authors review the use of magnetic resonance imaging (MRI), magnetic resonance spectroscopy, functional MRI, and three-dimensional MRI, and consider the rapidly developing body of pathologic information they have yielded. On the treatment side, the focus is on recently approved medications (Novantrone), new indications for medications (CHAMPS Trial), medications in development (Oral Interferon Tau, Oral Copaxone, and Oral Cellcept), immunosuppressive therapy for both progressive disease and symptomatic therapy; the current medications for treating relapsing-remitting MS (Avonex, Betaseron, and Copaxone) are also discussed. For future directions, the authors present the current best thinking, as well as the latest discoveries in immunology relating to MS, including groundbreaking B-cell research, its applications to specific immunotherapies, and the use of immune markers for tracking the disease. Additional chapters cover the mechanism and application of myelin repair, bone marrow transplantation, combination therapy, and specific immunomodulatory treatments. Comprehensive and up-to-date, Multiple Sclerosis: Etiology, Diagnosis, and New Treatment Strategies reviews all the current immunological, neuropsychological, imaging, and pregnancy issues associated with MS and shows how each is contributing to the still ongoing development of more efficacious therapies.

Multiple Sclerosis --- Multiple sclerosis. --- Sclérose en plaques --- therapy. --- diagnosis. --- etiology. --- Multiple sclerosis --- Diagnosis --- Demyelinating Autoimmune Diseases, CNS --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Autoimmune Diseases of the Nervous System --- Demyelinating Diseases --- Autoimmune Diseases --- Nervous System Diseases --- Immune System Diseases --- Diseases --- Neurology --- Medicine --- Health & Biological Sciences --- Treatment. --- Diagnosis. --- MS (Disease) --- Sclerosis, Multiple --- Medicine. --- Neurology. --- Medicine & Public Health. --- Demyelination --- Myelin sheath --- Virus diseases --- Nervous system --- Neuropsychiatry --- Neurology .

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Multiple Sclerosis (MS) is an enigmatic immune mediated disease of the central nervous system that affects about 350,000 individuals in the US, and many more around the world. The mechanism of this disease is largely unknown and there is no cure for it. However, there are several well-characterized experimental animal models that help us understand and speculate about potential mechanisms of pathology in this disease. Many of the experimental therapies designed for this disease rely on testing the drugs in animal models before using it in clinical trials. This book combines for the first time the different experimental models for MS (including immune-mediated and viral) under one roof, and highlights aspects that are different or shared among these experimental models. It’s aim is to improve our understanding of this devastating disease and help us think about potential additional therapies for it. Experimental Models of Multiple Sclerosis will be an important reference for neuroscientists, neurologists, immunologists, microbiologists (especially virologists) and pathologists (especially neuropathologists). Health professionals involved with MS, and medical students will also benefit from this book.

Multiple sclerosis. --- Multiple sclerosis --- Animal models. --- MS (Disease) --- Sclerosis, Multiple --- Demyelination --- Myelin sheath --- Virus diseases --- Diseases --- Immunology. --- Medical virology. --- Neurosciences. --- Pathology. --- Neurology. --- Virology. --- Medicine --- Nervous system --- Neuropsychiatry --- Disease (Pathology) --- Medical sciences --- Medicine, Preventive --- Neural sciences --- Neurological sciences --- Neuroscience --- Medical microbiology --- Virology --- Immunobiology --- Life sciences --- Serology --- Neurology . --- Microbiology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

La sclerosi multipla (SM) rappresenta la seconda causa di disabilità neurologica nel giovane adulto, dopo i traumi cranici. Negli ultimi anni, l'introduzione di nuovi farmaci, potenzialmente in grado di modificare il decorso della malattia, ha richiamato l'attenzione sui costi sociali della SM e sugli aspetti farmaco-economici. Si sono avanzati, da un lato, timori che il costo dei nuovi farmaci costituisca un onere insostenibile per il sistema sanitario. Dall'altro lato, recenti studi economici hanno sottolineato l'importanza di una valutazione inserita in una prospettiva più ampia, considerando la possibilità che le nuove terapie possano ridurre i costi sociali di malattia nel lungo termine, ritardando o evitando lo sviluppo di invalidità. Questo volume rivede la letteratura internazionale sui costi sociali della SM, e gli studi farmaco-economici sui nuovi farmaci per la malattia. In futuro, sarà necessario implementare studi metodologicamente rigorosi, in particolare di tipo comparativo. Estremamente importante sarà la raccolta di dati prospettici su ampie popolazioni di pazienti, per valutare il reale impatto delle nuove terapie sullo sviluppo di disabilità a lungo termine. Le informazioni attualmente disponibili derivano infatti essenzialmente dalle sperimentazioni terapeutiche, che si riferiscono a casistiche selezionate di pazienti seguiti per brevi periodi (2-3 anni). L'acquisizione di questi dati sarà di importanza critica per migliorare la stima del rapporto costi/benefici con l'impiego dei nuovo farmaci e valutare le priorità in politica sanitaria negli anni a venire.

Multiple sclerosis. --- Cost effectiveness. --- Neurosurgery. --- Medicine. --- Family medicine. --- Neurology. --- Medicine/Public Health, general. --- General Practice / Family Medicine. --- Public Health. --- Medicine --- Nervous system --- Neuropsychiatry --- Family practice (Medicine) --- General practice (Medicine) --- Physicians (General practice) --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Nerves --- Neurosurgery --- Diseases --- Surgery --- Health Workforce --- General practice (Medicine). --- Public health. --- Neurology . --- Community health --- Health services --- Hygiene, Public --- Hygiene, Social --- Public health services --- Public hygiene --- Social hygiene --- Health --- Human services --- Biosecurity --- Health literacy --- Medicine, Preventive --- National health services --- Sanitation